Paxlovid: Study finds no benefit in Pfizer Covid pill for younger adults
Paxlovid: Study finds no benefit in Pfizer Covid pill for younger adults
The US has spent more than $10 billion purchasing the drug and making it available.
www.syracuse.com
WASHINGTON (AP) — Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
The results from a 109,000-patient Israeli study are likely to renew questions about the U.S. government’s use of Paxlovid, which has become the go-to treatment for COVID-19 due to its at-home convenience. The Biden administration has spent more than $10 billion purchasing the drug and making it available at thousands of pharmacies through its test-and-treat initiative.